Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

AdaptHealth Earnings Preview

AdaptHealth (NASDAQ:AHCO) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts estimate that AdaptHealth will report an earnings per share (EPS) of $0.34.

AdaptHealth (NASDAQ:AHCO) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here’s what investors need to know before the announcement.

Analysts estimate that AdaptHealth will report an earnings per share (EPS) of $0.34.

AdaptHealth bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company missed EPS by $0.08, which was followed by a 3.52% drop in the share price the next day.

Here’s a look at AdaptHealth’s past performance and the resulting price change:

Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020
EPS Estimate 0.28 0.22 0.23 0.17
EPS Actual 0.20 0.17 0.01 -0.47
Price Change % -3.52% 0.56% 3.66% 0.19%

eps graph

Stock Performance

Shares of AdaptHealth were trading at $15.73 as of February 22. Over the last 52-week period, shares are down 50.06%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.

To track all upcoming earnings announcements, click here to use Benzinga Earnings Calendar.

Total
0
Shares
Related Posts
Read More

Recap: United States Steel Q2 Earnings

United States Steel (NYSE:X) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:15 PM. Here's what investors need to know about the announcement. Earnings United States Steel missed estimated earnings by 0.26%, reporting an EPS of $3.86 versus an estimate of $3.87.

X

Read More

Cara Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results

Cara Therapeutics, Inc. (NASDAQ: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2021.

CARA